BioWorld International articles from September 2002

BioWorld International archives from September 2002

Microscience, Evotec collaborate to develop antimicrobial drugs.
September 4, 2002... LONDON -- Microscience Ltd. is forming a 50-50 joint venture company with the Hamburg, Germany, drug discovery services company Evotec OAI to develop small-molecule antimicrobial drugs based on targets generated by Microscience's functional...

Danish presidency of EU says stem cell issue still on table.
September 4, 2002... BRUSSELS, Belgium -- Concern in the European parliament about a possible embargo on stem cell research has been countered by the Danish presidency of the European Union. Following complaints by the Parliament's industry and research...

Oxford BioMedica cuts back on programs to extend money.
September 4, 2002... LONDON -- Gene therapy specialist Oxford BioMedica plc said it is parking several of its research programs and slowing the expansion program begun in 2001, in order to eke out existing cash reserves and leave it with enough money to last until...

Evotec's licensing model keeps it a step ahead in difficult market.
September 4, 2002... MUNICH, Germany -- Evotec OAI AG licensed its patented technology for analysis of certain gene fragments in polymerase chain reactions to Roche Diagnostics GmbH, the German affiliate of Roche Diagnostics. The technology analyzes the melting...

EU drug industry defends use of genetically modified animals.
September 4, 2002... BRUSSELS, Belgium -- The main European drug industry association, the European Federation of Pharmaceutical Industries and Associations, has launched a stout defense of the use of genetically modified animals in biomedical research. In a...

Alizyme plc, of London, presented results of the Phase Ib program of ATL-962, a lipase inhibitor, at the International Congress of Obesity in Sao Paulo, Brazil, last week. (Other News To Note).
September 4, 2002... * Alizyme plc, of London, presented results of the Phase Ib program of ATL-962, a lipase inhibitor, at the International Congress of Obesity in Sao Paulo, Brazil, last week. The three Phase Ib trials involved 99 volunteers in groups of seven or...

Cambridge Antibody Technology Group plc. (Other News To Note).
September 4, 2002... * Cambridge Antibody Technology Group plc, of Melbourn, UK, said CAT-213 completed a single-dose Phase I/II challenge trial in hay fever. Preliminary results showed a significant effect on nasal patency (airflow through the nasal passages) and...

IsoTis NV. (Other News To Note).
September 4, 2002... * IsoTis NV, of Bilthoven, the Netherlands, said its founding CEO, Clemens van Blitterswijk, stepped down to concentrate his expertise on the company's research programs in substitution medicine. IsoTis expects to appoint a new CEO shortly....

Noxxon Pharma AG. (Other News To Note).
September 4, 2002... * Noxxon Pharma AG, of Berlin, completed a mezzanine financing round of 9.3 million [euro], defying a difficult venture capital climate in Germany. The round was led by Merlin Biosciences, of London and Luxembourg. Other members of the...

Oxagen Ltd, of Abingdon, UK, in-licensed rights to three polymorphisms, each of which represents a diagnostic marker for the detection of predisposition to osteoporosis. (Other News To Note).
September 4, 2002... * Oxagen Ltd., of Abingdon, UK, in-licensed rights to three polymorphisms, each of which represents a diagnostic marker for the detection of predisposition to osteoporosis. The company said it has added significant value to the polymorphisms,...

Oxford Natural Products Ltd. (Other News To Note).
September 4, 2002... * Oxford Natural Products Ltd., of Oxford, UK, said ONP-04, a prodrug of tetrahydrocannabinol, an active ingredient of cannabis, successfully completed Phase I trials in the treatment of pain. The company said the compound will enter Phase II...

Phytopharm plc. (Other News To Note).
September 4, 2002... * Phytopharm plc, of Godmanchester, UK, announced results of a Phase IIa study of P54, a derivative of the spice tumeric, in the treatment of inflammatory bowel disease. The aim of the 27-patient study was to assess whether treatment with P54...

Kudos raises 30m [pounds sterling] for clinical development of cancer drugs.
September 11, 2002... LONDON -- Kudos Pharmaceuticals Ltd. raised 29.5 [pounds sterling] million (US$45.9 million) in third-round funding with plans to take its two lead cancer treatments through Phase II and push further compounds into Phase I. Chief Financial...

Gene deletion from colorectal tumors might dictate success.
September 11, 2002... LONDON -- The time when patients with cancer have chemotherapy tailored to the genetic make-up of their tumors is fast approaching. Researchers in Switzerland have identified a gene which, when lost from a tumor, reduces the success of a...

With new premises, Tropos launches 15m [euro] funding round.
September 11, 2002... PARIS -- Trophos will inaugurate new business premises on Sept. 13 at the Luminy science park near Marseille, where the company is based. The facility, which comprises 1,200 square meters of laboratory space, will be opened by the French...

Session examines avoiding legal pitfalls in clinical trials. (3rd Annual BIA European CEO And Investor Conference).
September 11, 2002... LONDON -- Companies are facing increasing challenges in their clinical development programs: There is a need to do not only more studies, but more complex studies; companies are coming under pressure to reduce product development time; and they...

Committee provides support for European biotechnology.
September 11, 2002... BRUSSELS, Belgium -- Further support for the promotion of Europe's biotechnology industry has come from one of the European Union's principal consultation bodies, the Economic and Social Committee. Reviewing the EU's 30-point action plan...

EU legislation on GMO exports weak, parliament member says.
September 11, 2002... BRUSSELS, Belgium -- The European Parliament will start formal discussions today of another proposal for European legislation on biotechnology. Its committee on the environment, public health and consumer policy will examine plans for a...

Medivir to lose CEO Frick to venture capital fund.
September 11, 2002... One of Sweden's most experienced biotechnology industry executives is quitting his post in order to take on a new role as a venture capitalist. Jonas Frick has been CEO of Huddinge-based Medivir AB for the past six years. Six months from...

MediGene reports positive early results in liver cancer.
September 11, 2002... MUNICH, Germany -- MediGene AG, of Martinsried, announced positive results from a Phase I trial of a virus genetically engineered to treat a form of liver cancer. The results are welcome news for one of Germany's most prominent...

Avidex third round raises 11.5m [pounds sterling] for T-cell receptors.
September 11, 2002... LONDON -- Avidex Ltd., of Oxford, raised 11.5 million [pounds sterling] (US$17.9 million) in third-round funding, which should enable it to take several of its T-cell receptor products through to the clinic in 2004. Avidex CEO James Noble...

New controls on genetically modified animals needed in UK.
September 11, 2002... LONDON -- New controls are needed before genetically modified animals arrive on UK farms or are released into the environment, the government's biotechnology advisers said last week. Genetically modified and cloned animals in conventional...

ScanBalt BioRegion looking to create global biotech region.
September 11, 2002... ROSTOCK, Germany -- During the Middle Ages, a group of cities in northern Germany banded together to form a co-operative trading network that developed into the Hanseatic League, which grew in power and came to dominate medieval trade across...

Acambis plc. (Other News To Note).
September 11, 2002... Acambis plc, of Cambridge, UK, announced positive results from a Phase I trial of the smallpox vaccine it is developing for the U.S. government. ACAM1000 was compared to Dryvax, the smallpox vaccine that was used in the worldwide smallpox...

Amsterdam Molecular Therapeutics, of Amsterdam, the Netherlands, signed a license with Schering-Plough-Corp. for the use of interieukin-10 in ex vivo gene therapy in inflammatory diseases of the gastrointestinal tract. (Other News To Note).
September 11, 2002... Amsterdam Molecular Therapeutics, of Amsterdam, the Netherlands, signed a license with Schering-Plough-Corp. for the use of interieukin-10 in ex vivo gene therapy in inflammatory diseases of the gastrointestinal tract. AMT is developing the...

Astex Technology Ltd., of Cambridge, UK, a specialist in the use of high-throughput X-ray crystallography in structure-based drug discovery, said it received its first milestone payment from Aventis Pharmaceuticals for its work in solving the 3-dimensional structure of a human cytochrome P450. (Other News To Note).
September 11, 2002... Astex Technology Ltd., of Cambridge, UK, a specialist in the use of high-throughput X-ray crystallography in structure-based drug discovery, said it received its first milestone payment from Aventis Pharmaceuticals for its work in solving the...

Cambridge Antibody Technology Group plc, of Melbourn, UK, said its lead product, D2E7, has entered two further clinical studies, a Phase III trial in juvenile rheumatoid arthritis and a Phase II/III in Crohn's disease. (Other News To Note).
September 11, 2002... Cambridge Antibody Technology Group plc, of Melbourn, UK, said its lead product, D2E7, has entered two further clinical studies, a Phase III trial in juvenile rheumatoid arthritis and a Phase II/III in Crohn's disease. The trials are being...

Genetic Technologies Ltd., of Melbourne, Australia, sold a license for its patented technology for analyzing the noncoding parts of the genome to Perlegen Sciences Inc. (Other News To Note).
September 11, 2002... Genetic Technologies Ltd., of Melbourne, Australia, sold a license for its patented technology for analyzing the noncoding parts of the genome to Perlegen Sciences Inc. The specific terms of the deal, the third involving the technology Genetic...

Microscience Ltd. (Other News To Note).
September 11, 2002... Microscience Ltd., of Wokingham, UK, entered an agreement with the University System of Maryland to license the university's Bactofection DNA vaccine technology, making it possible to deliver DNA vaccines orally. Microscience will marry this...

Provalis plc. (Other News To Note).
September 11, 2002... Provalis plc, of Deeside, UK, said that it is pulling out of vaccines research to concentrate its research and development efforts on diagnostics, and has put its vaccines programs up for sale. The company said it expects to divest the...

Transgene SA. (Other News To Note).
September 11, 2002... Transgene SA, of Strasbourg, France, appointed Philippe Poncet chief financial officer in succession to Paul Bikard. Poncet, 35, comes from Lyon, France-based Aventis CropScience, where he spent 11 years in the corporate finance department,...

Vernalis Group plc. (Other News To Note).
September 11, 2002... Vernalis Group plc, of Wokingham, UK, saw its shares rise by 20.5 pence to 52.5 pence on Sept. 3 when the company announced positive results in a Phase IV trial of frovatriptan in the prevention of menstrual migraine. The company said it will...

GPCRs focus of deals involving Biovitrium, BioFocus, BioXell.
September 18, 2002... G protein-coupled receptors, the superfamily of membrane-spanning proteins involved in diverse signaling processes, are the subject of two drug discovery collaborations unveiled last week by European biotechnology firms. Sweden's largest...

Kidney disease gene discovery holds clues for renal fibrosis.
September 18, 2002... LONDON -- A team of European researchers identified a fourth gene involved in the rare kidney disorder nephronophthisis. The discovery should, the researchers predict, eventually allow new insights into the mechanism underlying the much...

Actelion moving tezosentan into Phase III for acute heart failure.
September 18, 2002... Swiss drug development firm Actelion Ltd. is planning to move the acute heart failure drug candidate Veletri (tezosentan) into Phase III trials before the year's end, following the release of promising data from a Phase II dose-optimization...

Xenova strengthens position, raises 9.9m [pounds sterling] in rights issue.
September 18, 2002... LONDON -- Xenova Group plc took on the extremely depressed markets, announcing a 9.9 million [pounds sterling] (US$15.2 million) rights issue to fund further development of its pipeline. The 8-for-33 rights issue represents a discount of 25...

Cenix BioScience raises 5m [euro] to develop RNAi technology.
September 18, 2002... MUNICH, Germany -- Cenix BioScience GmbH, a privately held start-up specializing in RNA-mediated interference (RNAi) technologies and therapeutics, closed a (5 million financing round. The Dresden-based company plans to use the financing to...

UK Stem Cell Bank established to manage cell research lines.
September 18, 2002... LONDON -- The Medical Research Council announced the establishment of the UK Stem Cell Bank, a single national, independent institute to manage and supply ethically approved, quality-controlled stem cell lines for research. The 2.6 million...

Lund University establishing stem cell research institute.
September 18, 2002... LUND, Sweden -- Lund University is establishing a new institute for stem cell research, following its receipt of SEK12 million (US$1.3 million) funding from the Swedish Research Council to set up a research network that will investigate...

French researchers discover genetic origin for colon cancer.
September 18, 2002... PARIS -- French researchers have discovered a new genetic explanation for the development of colon cancer, which contradicts the conventional assumption that mutation of the APC gene is the starting point for that cancer. Researchers at...

Euroscreen granted U.S. patent covering human CCR5 receptor.
September 18, 2002... PARIS -- Euroscreen SA has been granted a U.S. patent covering a specific G protein-coupled receptor sequence in the human CCR5 receptor. The Belgian company is focusing on research into the therapeutic potential of G protein-coupled...

CellFactors' Skeletex displays ability to form bone in muscle.
September 18, 2002... LONDON -- CellFactors plc said it made a breakthrough with its bone-regeneration product, Skeletex, demonstrating its ability to induce spontaneous formation of new bone in muscle, the orthopedic industry's key test of the effectiveness of...

Adprotech Ltd. (Other News To Note).
September 18, 2002... Adprotech Ltd., of Cambridge, UK, was granted orphan drug status by the European Medicines Evaluation Agency for APT070 in the prevention of graft dysfunction in kidney transplants. APT070 is scheduled to enter Phase II trials at a number of...

Ark Therapeutics Ltd. (Other News To Note).
September 18, 2002... Ark Therapeutics Ltd., of London, started clinical trials of EG010, a point-of-care test kit for cardiovascular disease. The kit measures oxidized-low density lipoproteins (Ox-LDL), which are found in the fatty plaques that line the walls of...

BioImage A/S. (Other News To Note).
September 18, 2002... BioImage A/S, of Copenhagen, Denmark, made a number of board changes intended to reflect its transition from a platform technology company to a fully fledged drug discovery outfit. It promoted nonexecutive board member Edwin Moses to chairman....

Biosearch Italia SpA, of Milan, Italy, said it received funding of 6.5 million [euro] from the Italian Ministry of Productive Activities to support development of its novel antibiotic compounds. (Other News To Note).
September 18, 2002... Biosearch Italia SpA, of Milan, Italy, said it received funding of 6.5 million [euro] from the Italian Ministry of Productive Activities to support development of its novel antibiotic compounds. Forty percent of the funding comprises a...

ML Laboratories plc. (Other News To Note).
September 18, 2002... ML Laboratories plc, of Warrington, UK, said it changed its mind about selling its respiratory division, Innovate Biomed (IB), after agreeing to a deal with an undisclosed pharmaceutical company to market and distribute two drugs in IB's...

Migragen AG. (Other News To Note).
September 18, 2002... Migragen AG, of Tuebingen, Germany, appointed Lucio van Rooijen president and chief executive officer. Van Rooijen worked for 12 years in the pharmaceutical division of Bayer AG. Most recently, van Rooijen was vice president for business...

Mologen AG. (Other News To Note).
September 18, 2002... Mologen AG, of Berlin, will work together with a major U.S. pharmaceutical concern to carry out a feasibility study on a veterinary vaccine based on Mologen's MIDGE vector technology. Mologen's vector combines elements of both viral and plasmid...

PowderJect Pharmaceuticals plc. (Other News To Note).
September 18, 2002... PowderJect Pharmaceuticals plc, of Oxford, UK, started a Phase I study of its powder injection flu vaccine, Fluvirin. The study will compare Fluvirin as a powder, administered by needle-free injection, to the company's currently marketed liquid...

Proteom Ltd. , of Cambridge, UK, signed up SC Biosciences Corp., of Tokyo, to market Proteom's bioinformatics technology to Japanese pharmaceutical and biotechnology companies. (Other News To Note).
September 18, 2002... Proteom Ltd., of Cambridge, UK, signed up SC Biosciences Corp., of Tokyo, to market Proteom's bioinformatics technology to Japanese pharmaceutical and biotechnology companies. The technology can be used in structure-based drug design to design...

ReNeuron Holdings plc, of Guildford, UK, said it has overcome the problems of genetic instability it was having in certain of its cell lines. (Other News To Note).
September 18, 2002... ReNeuron Holdings plc, of Guildford, UK, said it has overcome the problems of genetic instability it was having in certain of its cell lines. It has secured worldwide rights to a patent from Amrad Corp Ltd., of Australia, to use c-Myc and...

Ribotargets Ltd. (Other News To Note).
September 18, 2002... Ribotargets Ltd., of Cambridge, UK, which uses structure-based technologies to develop antibiotics and anticancer drugs, is joining 10 other groups in a European Union project to discover antibacterials and antifungals that work by inhibiting...

Skyepharma plc, of London, acquired certain Pacific Rim marketing rights for Solarase, its topical cream for the precancerous skin condition actinic keratosis, from Meditech Research Ltd., of Melbourne, Australia. (Other News To Note).
September 18, 2002... Skyepharma plc, of London, acquired certain Pacific Rim marketing rights for Solarase, its topical cream for the precancerous skin condition actinic keratosis, from Meditech Research Ltd., of Melbourne, Australia. Skyepharma gains rights in...

KS Biomedix, Nycomed sign deal for TransMID 107 cancer therapy.
September 25, 2002... LONDON -- KS Biomedix Holdings plc agreed to a licensing deal worth up to US$60 million for its TransMID 107 brain cancer treatment with Nycomed Group. The license includes rights to the initial indication in recurrent glioma, plus...

BCLC says BRCA1 increases risk of other cancers in women.
September 25, 2002... LONDON -- The discovery that women who inherit a mutant copy of the BRCA1 gene are at increased risk of developing a whole range of cancers in addition to cancer of the breast and ovary highlights the need for new screening techniques for...

Neuro3d raises 20m [euro] privately to fund work in CNS disorders.
September 25, 2002... PARIS -- Neuro3d, a biotechnology company set up in 2000 to discover and develop drugs for disorders of the central nervous system, raised a further 20 million [euro] in a second round of financing. The round was led by two European venture...

Modex, IsoTis plan to merge programs in orthopedics, skin.
September 25, 2002... Modex Therapeutics Ltd. and IsoTis NV agreed to a stock-based merger that would create what the two companies are billing as Europe's top biosurgery company, with a combined pro forma cash position of 92 million [euro], a work force of 173 and...

EU urges use of biotechnology in and from developing world.
September 25, 2002... BRUSSELS, Belgium -- The European Union has given strong backing to biotechnology's potential in the developing world in a submission last week to the World Trade Organization. It tabled a plan to help developing countries reap benefits...

European parliament aims to tighten GM trade rules. (European Union Roundup).
September 25, 2002... BRUSSELS, Belgium -- The European Parliament's committee on the environment, public health and consumer protection called last week for some 40 amendments to tighten up draft European Union rules on trade in genetically modified organisms. ...

Hit back at us with EU GMO ban, says FOE. (European Union Roundup).
September 25, 2002... Friends of the Earth Europe has urged the European Union to target U.S.-exported genetically modified foods in retaliation for the United States' violation of World Trade Organization rules on foreign sales corporations. The WTO recently...

European biotech association seeks management. (European Union Roundup).
September 25, 2002... Emerging Biopharmaceutical Enterprises, a specialized group of 34 research-based companies developing new therapies using biosciences technologies, has grown to the point where it needs an executive manager. The group, established just two...

Eirx pharma formed through three-way Anglo-Irish merger.
September 25, 2002... DUBLIN, Ireland -- Billam plc, a London-based investment vehicle, has orchestrated a three-way merger between early stage portfolio companies and has invested 1.4 million [pounds sterling] (US$2.2 million) in the enlarged entity. The...

Cardion closes 10m [euro] financing to fund CRB-15, stem cell work.
September 25, 2002... MUNICH, Germany -- Cardion AG, a company focused on treatments for heart and inflammatory diseases, has secured 11.5 million [euro] of funding. Cardion, of Erkrath, which was founded in 1996, has raised a total of more than 60 million...

Acambis completes manufacture of first batch of smallpox vaccine.
September 25, 2002... LONDON -- Acambis plc said it has completed the manufacture of the first batch of 209 million doses of a new smallpox vaccine destined for the U.S. National Pharmaceutical Stockpile, and reported positive results in a second Phase I trial of...

Zentaris, Access Oncology enter $30m alliance for cancer drug.
September 25, 2002... MUNICH, Germany -- Zentaris AG signed a license agreement with Access Oncology Inc. to develop perifosine for the treatment of cancer in a deal potentially worth more than $30 million. Access Oncology, of New York, will make up-front and...

Celltech Group plc, of Slough, UK, said partner Pharmacia Corp., of Peapack, N.J., completed reformulation of Celltech's CDP 870 and that Phase III development in rheumatoid arthritis will begin next month. (Other News To Note).
September 25, 2002... Celltech Group plc, of Slough, UK, said partner Pharmacia Corp., of Peapack, N.J., completed reformulation of Celltech's CDP 870 and that Phase III development in rheumatoid arthritis will begin next month. The move into Phase III will trigger...

F2G Ltd. (Other News To Note).
September 25, 2002... F2G Ltd., of Manchester, UK, confirmed the completion of its first-round funding, raising 4.3 million [pounds sterling] (US$6.7 million). The company will use the money to take on more staff and expand drug discovery efforts based around...

IT-Omics, the bioinformatics subsidiary of Lille, France-based Genfit SA, entered a technical partnership with the life sciences division of IBM Corp, in France for the development of data manipulation and analysis software based on the DiscoveryLink platform that IBM developed specifically for life sciences research. (Other News To Note).
September 25, 2002... IT-Omics, the bioinformatics subsidiary of Lille, France-based Genfit SA, entered a technical partnership with the life sciences division of IBM Corp, in France for the development of data manipulation and analysis software based on the...

Mobius Genomics Ltd. (Other News To Note).
September 25, 2002... Mobius Genomics Ltd., of Exeter, UK, was awarded a European patent on its technology for high-throughput, real-time human genome sequencing. The technique is so sensitive that whole genomes can be sequenced and compared, down to base-pair...

NicOx SA. (Other News To Note).
September 25, 2002... NicOx SA, of Sophia-Antipolis, France, said the FDA accepted its investigational new drug application for a Phase II trial of NCX 701, a nitric oxide-releasing derivative of paracetamol (acetaminophen) it is developing for the treatment of...

Genset shareholders accept bid from Serono; integration begins.
September 25, 2002... PARIS -- The shareholders of Genset SA overwhelmingly accepted the 107 million [euro] cash offer received in mid-July from Geneva-based Serono SA. By the closing date of Sept. 12, the company's French subsidiary, Serono France Holding SA,...

NascaCell GmbH, of Tutzing, Germany, acquired a nonexclusive, worldwide license from Applied Molecular Evolution Inc., of San Diego, for patents on directed molecular evolution. (Other News To Note).
September 25, 2002... NascaCell GmbH, of Tutzing, Germany, acquired a nonexclusive, worldwide license from Applied Molecular Evolution Inc., of San Diego, for patents on directed molecular evolution. The companies declined to disclose financial terms of the...

Novozymes A/S, of Bagsvaerd, Denmark, said it entered a joint research project with Neugenesis Corp., of San Carlos, Calif., to develop a new method for producing antibodies, which will draw on its strengths in gene technology and the latter firm's patented monoclonal antibody technology. (Other News To Note).
September 25, 2002... Novozymes A/S, of Bagsvaerd, Denmark, said it entered a joint research project with Neugenesis Corp., of San Carlos, Calif., to develop a new method for producing antibodies, which will draw on its strengths in gene technology and the latter...

Pharmagene plc, of Royston, UK, signed a contract giving Boehringer Ingelheim Pharma KG, of Ingelheim, Germany, access to its Phase ZERO compound validation service. (Other News To Note).
September 25, 2002... Pharmagene plc, of Royston, UK, signed a contract giving Boehringer Ingelheim Pharma KG, of Ingelheim, Germany, access to its Phase ZERO compound validation service. That allows companies to profile compounds in human tissues and select...

Oxford GlycoSciences plc, of Abingdon, UK, agreed to a research collaboration with the Center for Drug Evaluation and Research of the FDA to use industrial-scale proteomics to find protein markers that are predictive of drug toxicity. (Other News To Note).
September 25, 2002... Oxford GlycoSciences plc, of Abingdon, UK, agreed to a research collaboration with the Center for Drug Evaluation and Research of the FDA to use industrial-scale proteomics to find protein markers that are predictive of drug toxicity. The...

PharmaMar. (Other News To Note).
September 25, 2002... PharmaMar, a subsidiary of Madrid, Spain-based Zeltia Group, said the drug candidate ET-743 (Yondelis) showed evidence of efficacy in childhood and adult cancers unresponsive to conventional therapy. In one dose-finding study of 13 patients...

Schering AG, of Berlin, entered into a collaboration with Atugen AG, also based in Berlin, to validate drug targets associated with cancer. The agreement provides for Schering to make an up-front payment to Atugen. (Other News To Note).
September 25, 2002... Schering AG, of Berlin, entered into a collaboration with Atugen AG, also based in Berlin, to validate drug targets associated with cancer. The agreement provides for Schering to make an up-front payment to Atugen. Annual license fees, research...

SkyePharma plc, of London, said it is on track to move into profitability in 2002 following the launch of Paxil CR, a controlled-release formulation of the antidepressant, by its partner, GlaxoSmithKline plc, of London. (Other News To Note).
September 25, 2002... SkyePharma pic, of London, said it is on track to move into profitability in 2002 following the launch of Paxil CR, a controlled-release formulation of the antidepressant, by its partner, GlaxoSmithKline plc, of London. lan Gowrie-Smith,...

SR Pharma plc. (Other News To Note).
September 25, 2002... SR Pharma plc, of London, said it received approval for a Phase II trial of SRP 299 in atopic dermatitis (eczema) in children. The trial, involving 120 children aged 5 to 16, is expected to start in the fourth quarter.

Transgene SA. (Other News To Note).
September 25, 2002... Transgene SA, of Strasbourg, France, said it was granted 10 new patents this year protecting its vector technology portfolio, six of them in the U.S. and four in Europe. They cover its technologies for the delivery of viral and nonviral...

Zealand Pharma A/S. (Other News To Note).
September 25, 2002... Zealand Pharma A/S, of Glostrup, Denmark, said the Type II diabetes drug candidate ZP10 was well tolerated and displayed no side effects in a Phase I/II trial in 28 patients. No safety issues were identified in the double-blind,...